US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management.
The San Diego-based company is developing oral, first-in-class small molecules aimed at serious rare diseases with genetic drivers—namely KCNT1-related epilepsy and Charcot-Marie-Tooth disease type 2C (CMT2C). Additional investors included Canaan, Droia Ventures and Euclidean Capital.
The funds will support continued development of Actio’s lead candidates: ABS-1230, a KCNT1 inhibitor slated to enter a Phase I trial later this year, and ABS-0871, a TRPV4 inhibitor already in early-stage testing. Both programs target ultra-rare conditions that affect around 2,500 individuals each in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze